Infectious Disease

Closing out their discussion on recurrent clostridium difficile infection management, experts share closing thoughts and hopes for the future.

Panelists review unmet needs in clostridium difficile infection management and consider how medical policies are evolving to address them.

Shared insight on the process to gain access to fecal microbiota transplant for patients with clostridium difficile infection.

A focused discussion on the barriers to fecal microbiota transplant for patients with clostridium difficile infection.

Experts focus on the current state of fecal microbiota transplant as a treatment option for clostridium difficile infection.

Panelists take a step back to consider the broader challenges in managing patients with clostridium difficile infection.

In an interview conducted before the highly transmissible Omicron coronavirus variant began driving another wave of infections, Peter Hotez, MD, PhD, FASTMH, discussed the struggle public health officials and scientists have in fighting false beliefs about vaccinations.

This year's most-viewed content in infectious disease was dominated by COVID-19, as the Delta variant continued to strain the US health care system. It also included news about Clostridioides difficile.

Debra Patt, MD, PhD, MBA, of Texas Oncology, and Lucio Gordan, MD, of Florida Cancer Specialists, MD, presented data from a study they conducted in partnership with the Community Oncology Alliance and Avalere Health.

When a flu season is mild, it can make developing a vaccine for the following season a bit more difficult as it can be hard to find the right match, but on the other hand, the US health system could benefit from less stress this winter given the unrelenting demands posed by COVID-19, says Leslie Kantor, PhD, MPH, chair and professor of the Department of Urban-Global Public Health, Rutgers School of Public Health.

Payer participants consider how they proactively risk stratify patients for clostridium difficile infection recurrence.

Two doses of the Moderna COVID-19 vaccine have reduced efficacy against the Omicron variant; a federal appeals court reinstates the Biden administration’s health care worker vaccine mandate in 26 states; a new combination therapy may reduce breast cancer progression.

A brief review of the role of bezlotoxumab therapy for patients at high risk for clostridium difficile infection recurrence.

An overview on how the cost of therapy for recurrent clostridium difficile infection may impact treatment planning.

Focused discussion on the use of fidaxomicin for clostridium difficile infection, and possible barriers to the selection of this agent.

Misinformation about flu vaccines must be dealt with immediately, according to Leslie Kantor, PhD, MPH, chair and professor of the Department of Urban-Global Public Health, Rutgers School of Public Health.

Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.

Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.

Results of a nationwide retrospective cohort study show maternal infection with syphilis, gonorrhea, or chlamydia was associated with an increased risk of preterm birth.

The report briefly explained the policy options that policymakers can use to help address challenges related to vaccine research and development, testing, and manufacturing, as well as the economic challenges related to vaccine development for infectious diseases.

A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.

A broad view on the impact of recurrent clostridium difficile infection on patients and the healthcare system at large.

A multifaceted approach focused on enforcing basic infection prevention practices and promoting education about Clostridioides difficile (C difficile) transmission led to a reduction in the number of infections in a hospital setting.

The FDA decision was followed by a CDC advisory panel meeting Friday, and as expected, CDC Director Rochelle Walensky, MD, MPH, who has spoken in favor of booster shots, signed off on the plan.

Experts focus on recurrent clostridium difficile infection to define risk factors and discuss impact on patient outcomes.